curacle co., ltd. Logo

curacle co., ltd.

Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.

365270 | KO

Overview

Corporate Details

ISIN(s):
KR7365270008
LEI:
Country:
South Korea
Address:
서울특별시 서초구 효령로 23-1, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Curacle Co., Ltd. is a biopharmaceutical company established in 2016, specializing in the research and development of innovative drugs for intractable diseases. The company focuses on conditions arising from vascular damage and the aging process, with a particular emphasis on treatments for diseases like diabetes and stroke. Leveraging its unique research and platform technologies, Curacle develops a pipeline of new drug candidates to address significant unmet medical needs. The company aims to create treatments with high commercial potential and marketability.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.1 KB
2025-09-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.3 KB
2025-09-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-09-12 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 101.4 KB
2025-09-09 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 113.1 KB
2025-09-09 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (주주배정후 실권주 일반공모)
Korean 8.1 KB
2025-09-09 00:00
Share Issue/Capital Change
[기재정정]증권발행실적보고서
Korean 121.2 KB
2025-09-08 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
Korean 10.3 KB
2025-09-03 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
Korean 9.7 KB
2025-08-28 00:00
Share Issue/Capital Change
유상증자최종발행가액확정
Korean 11.4 KB
2025-08-28 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 41.6 KB
2025-08-28 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 260.5 KB
2025-08-28 00:00
Prospectus
[기재정정]투자설명서
Korean 2.2 MB
2025-08-13 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.08)
Korean 2.4 MB
2025-08-12 00:00
Interim Report
반기보고서 (2025.06)
Korean 939.8 KB

Automate Your Workflow. Get a real-time feed of all curacle co., ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for curacle co., ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for curacle co., ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Monte Rosa Therapeutics, Inc. Logo
Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.
United States of America
GLUE
Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.
South Korea
322970
MORISHITA JINTAN CO.,LTD. Logo
Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.
Japan
4524
MUROMACHI CHEMICALS INC. Logo
A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.
Japan
4885
MUSTANG BIO, INC. Logo
Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.
United States of America
MBIO
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea
017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden
NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France
NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America
NBTX
Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland
NANOFH

Talk to a Data Expert

Have a question? We'll get back to you promptly.